The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: A literature-based economic analysis

Original Research

(2076) Views  (864) Full article downloads

Authors: Jennifer Stephens, Kimbach Tran Carpiuc, Marc Botteman

Published Date December 2009 Volume 2010:3 Pages 31 - 36

DOI: http://dx.doi.org/10.2147/IJGM.S6944

Jennifer Stephens, Kimbach Tran Carpiuc, Marc Botteman

Pharmerit North America LLC, Bethesda, MD, USA

Objectives: To develop an economic analysis of the management of pleural effusions in patients with imatinib-resistant/intolerant chronic myelogenous leukemia (CML).

Methods: A cost of treatment analysis was conducted from the US payer perspective, based on resource utilization data for 48 patients with dasatinib-related pleural effusions at a large US cancer center. Probabilities of various procedures and treatment events were derived from published resource use data, supplemented with expert opinion. Cost data was derived from median reimbursements for relevant CPT codes for outpatient services and medical literature for inpatient services. Sensitivity analyses were conducted for types of procedures used. All costs were adjusted to US dollars (2007 rates).

Results: Sixty percent of pleural effusions were managed medically costing $750 per episode. Forty percent of pleural effusions were more significant (>25% of one lung volume), with half of those requiring invasive procedures. Cost of inpatient procedures was $10,616 for chest tube and $15,170 with pleural catheter. Cost of outpatient procedures was $713 for ultrasound thoracentesis and $4,598 for pleural catheter. The average cost of treating a pleural effusion was $2,062 to >$2,700 for all severity levels and ~$6,400 to >$9,000 for invasive procedures. Key cost drivers were invasive procedures and recurrence.

Conclusion: This economic analysis using actually observed treatment patterns suggests that the management of pleural effusion adverse events in CML patients is costly, requires intensive resource utilization, and may be an important factor in treatment selection.

Keywords: dasatinib, nilotinib, imatinib, adverse events, safety, cost, and cost analysis